SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

April 23, 2012 12:14 ET

Implant Sciences' Trace Detection Systems to Be Exhibited at Counter Terror Expo in London

Implant Sciences' Distributor Guartel Technologies to Feature Quantum Sniffers at Key Global Counter Terrorism Tradeshow

WILMINGTON, MA--(Marketwire - Apr 23, 2012) - Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that its Quantum Sniffer™ QS-H150 handheld explosives trace detector and the Quantum Sniffer™ QS-B220 benchtop explosives and narcotics trace detector will be exhibited at the Counter Terror Expo on April 25th and 26th, at the Grand Hall of the Olympia Exhibitions & Conference Centre in London, England. Implant Sciences' equipment will be featured by Implant Sciences' distributor Guartel Technologies Ltd. at stand #D176.

Counter Terror Expo is a critically acclaimed, highly specialized event for those defending against the threat posed from international terrorism. Counter Terror Expo brings experts in government, armed forces, security services, law enforcement and academia from all over the world together annually to share real-life experience, debate strategies, brainstorm issues, shape policy, and define effective counter-terrorism measures. The Expo showcases the very latest technology and techniques available to professionals in this vitally important arena. (www.counterterrorexpo.com)

"Having our products at this important global counter-terrorism event builds Implant Sciences' international presence in explosives trace detection. Our network of distributors around the world, including Guartel Technologies, is a critical asset to our Company," stated Implant Sciences' President and CEO Glenn D. Bolduc.

Guartel Technologies' product range includes counter improvised explosive device (IED) and search, explosives ordinance disposal (EOD), and de-mining. Its products are currently in service with police forces, security services, non-governmental organizations (NGOs), UK MoD, NATO, and other military forces world-wide. (www.guartel.com)

About the Quantum Sniffer™ QS-H150

The QS-H150 is a handheld explosives trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. The QS-H150 uses no radioactive materials and features a low-maintenance design that is self-calibrating and self-clearing, providing very high levels of operational availability.

About the Quantum Sniffer™ QS-B220

The QS-B220, introduced in May 2011, is a benchtop explosives and narcotics trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, plus narcotic substances. The QS-B220 continues the Implant Sciences tradition of freedom from radioactive materials, low total cost of ownership, and high operational availability.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 benchtop explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; that our success depends on our ability to obtain new patents and operate without infringing on the proprietary rights of others; that we may not obtain the patents we have applied for; that the validity and breadth of claims in technology patents involve complex legal and factual questions and, therefore, may be highly uncertain; that any patents we may obtain may be may be challenged and subsequently invalidated, that we may incur substantial costs in asserting our patent rights; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:
    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact